Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.61 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.57 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711168 | 0.86 | F10 (0.68) | F10RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL28265311 | 0.85 | RAB9A (0.68) | F10TMPRSS4DEGS1RAB9ASMN1; SMN2 | |
| SCHEMBL10178272 | 0.84 | F10 (0.72) | F10RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL890619 | 0.84 | F10 (0.72) | F10 | |
| SCHEMBL10178298 | 0.82 | F10 (0.64) | F10RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL890632 | 0.82 | F10 (0.71) | F10TMPRSS4DEGS1 | |
| SCHEMBL10178909 | 0.82 | F10 (0.85) | F10 | |
| SCHEMBL890676 | 0.80 | F10 (0.74) | F10 | |
| SCHEMBL10177909 | 0.79 | F10 (0.75) | F10 | |
| SCHEMBL12263717 | 0.79 | F10 (0.56) | F10DEGS1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077690-A1 | Quaternary amidino based inhibitors of factor xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1322637-A2 | QUATERNARY AMIDINO BASED INHIBITORS OF FACTOR XA | Millennium Pharmaceuticals, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002026731-A2 | QUATERNARY AMIDINO BASED INHIBITORS OF FACTOR XA | MILLENIUM PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077690-A1 | Quaternary amidino based inhibitors of factor xa | F12, TFPI, F11 | F10 15/4885TMPRSS4 625/4885DEGS1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.